CompletedNot applicableNCT05393154

Pilot Study of Biopsy Scanner for Evaluation of Bronchoscopic Small Biopsy Specimens to Determine Adequacy

The aim of the study is to assess the performance of Aquyre Biopsy Scanner technology (the FDA class I medical device) at determining if tissue from the lymph nodes and lung nodules, taken during a bronchoscopy procedure, is adequate for a diagnosis. The study will assess how well the Aquyre Biopsy Scanner can differentiate between tissue samples that meet certain requirements that allow for further diagnostic analysis and samples that do not.

Checked against the public recordLast updated Aug 18, 2026 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorAquyre Bioscience, Inc
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Aquyre Bioscience, Inc
Interventions being studied
Device: Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: 1. Signed informed consent prior to initiation of any study procedures. 2. Patient has a radiographically identified lung lesion(s) suspicious for malignancy and requiring histopathologic diagnosis. 3. Patient with a previously obtained (within 3 months) CT image showing at least one solid lesion equal to or greater than 1 cm in diameter or at least one semisolid lesion with a solid component of equal to or greater than 1 cm in diameter. 4. Bronchoscopic biopsy procedure is planned for the above lesion(s). Exclusion Criteria: 1. Patient does not meet the requirements to undergo biopsy as determined by the treating physician. 2. Patient is unable to provide a signed informed consent to participate in the study. 3. Patient has only ground glass lesion(s) that do not have a solid component.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Boston Medical CenterBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 18, 2026. Always confirm current availability with the study team.

View original record ↗